Lupin has received final approval for its Gabapentin Tablets USP, 600 mg and 800 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Pfizer Inc.'s Neurontin Tablets, 600 mg and 800 mg. Gabapentin Tablets USP, 600 mg and 800 mg had annual sales of around $180.7 million in the US as per IQVIA MAT June 2018.
Lupin's Gabapentin Tablets USP, 600 mg and 800 mg is the generic version of Pfizer's Neurontin Tablets, 600 mg and 800 mg. It is indicated for the treatment of postherpetic neuralgia in adults and adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
